表紙
市場調查報告書

全身性硬皮症(皮膚硬化症):開發平台分析

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2020

出版商 Global Markets Direct 商品編碼 213039
出版日期 內容資訊 英文 419 Pages
訂單完成後即時交付
價格
全身性硬皮症(皮膚硬化症):開發平台分析 Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2020
出版日期: 2020年07月31日內容資訊: 英文 419 Pages
簡介

所謂皮膚硬化症是皮膚和結締組織硬化的難治之症之一。主要的症狀有肌肉痛和關節痛,腫脹(膿腫),指尖出現潰瘍,腹部膨脹,腹瀉·便秘等。主要的治療藥有抗生素和止痛藥,免疫抑制劑等。

本報告提供全球各國的全身性硬皮症治療用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

全身性硬皮症概要

治療藥的開發

  • 全身性硬皮症開發中產品:概要
  • 全身性硬皮症開發中產品:比較分析

各企業正在開發的全身性硬皮症治療藥

大學/研究機關研究中的全身性硬皮症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

全身性硬皮症治療藥:開發中的產品一覽(各企業)

全身性硬皮症治療藥:研究中的產品一覽(大學/研究機關別)

全身性硬皮症開發治療藥的企業

  • Allergan Plc
  • Angion Biomedica Corp.
  • arGentis Pharmaceuticals, LLC
  • Bayer AG
  • BioLineRx, Ltd.
  • BiOrion Technologies B.V.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Corbus pharmaceuticals, Inc.
  • CSL Limited
  • Daval International Limited
  • Digna Biotech, S.L.
  • F. Hoffmann-La Roche Ltd.
  • Fibrocell Science, Inc.
  • GenKyoTex S.A.
  • GlaxoSmithKline Plc
  • iBio, Inc.
  • Inventiva SAS
  • Kadmon Corporation, LLC
  • miRagen Therapeutics, Inc.
  • Peptinov SAS
  • Ribomic Inc.
  • Stratatech Corporation
  • Vida Therapeutics Inc.
  • VivaCell Biotechnology Espana S.L.

全身性硬皮症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • abatacept
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • acALY-18
  • acetylcysteine
  • Aimspro
  • ANG-3070
  • ARG-201
  • belimumab
  • BL-1110
  • BOT-191
  • C-82
  • Cell Therapy for Dermatology and Immunology
  • disitertide
  • factor XIII (human)
  • FCX-013
  • GKT-831
  • GSK-2330811
  • IBIOCFB-03
  • IVA-337
  • JBT-101
  • KD-025
  • MGN-4220
  • nintedanib
  • Oligonucleotide for Scleroderma
  • onabotulinumtoxin A
  • PAT-048
  • PDX-002
  • PPV-06
  • RBM-006
  • riociguat
  • Small Molecule to Inhibit NFkB for Immunology and Oncology
  • Stem Cell Therapy for Crohns Disease, Systemic Sclerosis and Multiple Sclerosis
  • Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis
  • tocilizumab
  • VCE-0048
  • VEDA-1209
  • VTI-1000 Series

全身性硬皮症治療藥:開發中產品的最新趨勢

全身性硬皮症治療藥:開發暫停的產品

全身性硬皮症治療藥:開發中止的產品

全身性硬皮症相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12388IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis - Pipeline Review, H2 2020, provides an overview of the Systemic Sclerosis (Immunology) pipeline landscape.

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Sclerosis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 18, 9, 1, 37 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Systemic Sclerosis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Sclerosis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Sclerosis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Immunology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Systemic Sclerosis (Scleroderma) - Overview
  • Systemic Sclerosis (Scleroderma) - Therapeutics Development
  • Systemic Sclerosis (Scleroderma) - Therapeutics Assessment
  • Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development
  • Systemic Sclerosis (Scleroderma) - Drug Profiles
  • Systemic Sclerosis (Scleroderma) - Dormant Projects
  • Systemic Sclerosis (Scleroderma) - Discontinued Products
  • Systemic Sclerosis (Scleroderma) - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by Accuitis Pharmaceuticals Inc, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by AKL Research and Development Ltd, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by Allysta Pharmaceuticals Inc, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by Amgen Inc, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by AnaMar AB, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by Anima Biotech Inc, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals LLC, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by Aryogen Pharmed Co, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by AstraZeneca Plc, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by Atlantic Healthcare Plc, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by Aurora Research Institute LLC, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by Biogen Inc, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by Biomendics LLC, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by Blade Therapeutics Inc, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by BriaCell Therapeutics Corp, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Co, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by Cantargia AB, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by Capella Bioscience Ltd, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by Castle Creek Biosciences Inc, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by Celdara Medical LLC, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by ChemomAb Ltd, H2 2020
  • Systemic Sclerosis (Scleroderma) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2020
  • Systemic Sclerosis (Scleroderma) - Dormant Projects, H2 2020
  • Systemic Sclerosis (Scleroderma) - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020